Pittenger & Anderson Inc. Sells 36,956 Shares of Danaher Corporation $DHR

Pittenger & Anderson Inc. trimmed its position in shares of Danaher Corporation (NYSE:DHR) by 96.8% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 1,217 shares of the conglomerate’s stock after selling 36,956 shares during the quarter. Pittenger & Anderson Inc.’s holdings in Danaher were worth $241,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Sivia Capital Partners LLC raised its holdings in shares of Danaher by 6.3% in the second quarter. Sivia Capital Partners LLC now owns 2,009 shares of the conglomerate’s stock worth $397,000 after buying an additional 119 shares during the period. PFG Investments LLC boosted its holdings in Danaher by 4.6% during the 2nd quarter. PFG Investments LLC now owns 5,233 shares of the conglomerate’s stock valued at $1,034,000 after acquiring an additional 228 shares during the period. Robeco Institutional Asset Management B.V. grew its position in Danaher by 161.2% in the 2nd quarter. Robeco Institutional Asset Management B.V. now owns 175,724 shares of the conglomerate’s stock valued at $34,713,000 after acquiring an additional 108,448 shares during the last quarter. Naples Global Advisors LLC purchased a new stake in Danaher in the second quarter worth $270,000. Finally, Lecap Asset Management Ltd. lifted its position in shares of Danaher by 185.2% during the second quarter. Lecap Asset Management Ltd. now owns 4,073 shares of the conglomerate’s stock worth $805,000 after purchasing an additional 2,645 shares during the last quarter. 79.05% of the stock is owned by hedge funds and other institutional investors.

Key Danaher News

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Q4 results beat on EPS and management set FY2026 EPS guidance of $8.35–$8.50, which is above many street estimates and supports upside to earnings expectations. Danaher (DHR) Tops Q4 Earnings Estimates, Issues Solid 2026 Outlook
• Positive Sentiment: JPMorgan raised its price target to $275 and kept an overweight rating, signaling continued bullish sentiment among some large sell‑side shops. Benzinga
• Positive Sentiment: Molecular Devices (a Danaher business) announced a partnership to expand automated, AI‑ready research solutions — a product/market development that supports longer‑term growth in lab automation and software‑enabled sales. Molecular Devices Expands Access to Automated, AI-Ready Research Solutions
• Neutral Sentiment: Goldman Sachs trimmed its target slightly to $265 but maintained a buy rating, a modest calibration that still implies material upside but signals some caution. MarketScreener
• Neutral Sentiment: Earnings call transcripts and highlights show management emphasizing free cash flow and balance sheet strength, but a cautious tone on near‑term demand. These details provide context but are not unambiguously positive or negative. Danaher (DHR) Q4 2025 Earnings Call Transcript
• Negative Sentiment: Market commentary and headlines framed the report as “in‑line” on sales and cautioned investors that the post‑earnings dip may not be a good buying opportunity, which likely amplified selling pressure. Danaher Stock Plunge Does Not Represent A Good Entry Point
• Negative Sentiment: Despite the EPS beat, some outlets highlighted the stock drop after an essentially in‑line revenue/outlook, reinforcing bearish sentiment in the short term. Danaher drops after in-line earnings outlook
• Negative Sentiment: Valuation is elevated (P/E ~43) versus historical averages, which can make the stock more sensitive to any guidance softness or mixed indicators.

Insider Activity

In other Danaher news, SVP Brian W. Ellis sold 21,776 shares of the firm’s stock in a transaction that occurred on Wednesday, November 12th. The shares were sold at an average price of $219.23, for a total value of $4,773,952.48. Following the completion of the sale, the senior vice president directly owned 14,553 shares in the company, valued at $3,190,454.19. This trade represents a 59.94% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Teri List sold 3,298 shares of Danaher stock in a transaction on Tuesday, November 18th. The stock was sold at an average price of $226.50, for a total transaction of $746,997.00. Following the completion of the transaction, the director directly owned 20,762 shares in the company, valued at $4,702,593. This represents a 13.71% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 30,248 shares of company stock worth $6,609,663. Corporate insiders own 11.10% of the company’s stock.

Analyst Ratings Changes

DHR has been the topic of a number of research analyst reports. Robert W. Baird set a $251.00 price target on shares of Danaher in a report on Thursday. Jefferies Financial Group boosted their price objective on shares of Danaher from $255.00 to $265.00 and gave the company a “buy” rating in a research report on Wednesday. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Danaher in a research report on Monday, December 29th. Barclays lifted their price target on shares of Danaher from $225.00 to $250.00 and gave the company an “overweight” rating in a research note on Wednesday, October 22nd. Finally, Leerink Partners increased their price objective on Danaher from $260.00 to $270.00 and gave the stock an “outperform” rating in a research note on Friday, January 16th. Twenty analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $252.32.

Danaher Stock Down 0.4%

Danaher stock opened at $218.82 on Friday. The company has a quick ratio of 1.10, a current ratio of 1.87 and a debt-to-equity ratio of 0.35. The firm has a market cap of $154.56 billion, a P/E ratio of 43.42, a P/E/G ratio of 3.12 and a beta of 0.89. The business has a fifty day moving average of $230.60 and a two-hundred day moving average of $213.96. Danaher Corporation has a twelve month low of $171.00 and a twelve month high of $242.80.

Danaher (NYSE:DHR) last announced its quarterly earnings results on Wednesday, January 28th. The conglomerate reported $2.23 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.14 by $0.09. The business had revenue of $6.84 billion for the quarter, compared to the consensus estimate of $6.79 billion. Danaher had a return on equity of 10.81% and a net margin of 14.71%.The business’s revenue was up 4.6% compared to the same quarter last year. During the same period last year, the business posted $2.14 EPS. Danaher has set its FY 2026 guidance at 8.350-8.500 EPS. On average, analysts forecast that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, January 30th. Shareholders of record on Friday, December 26th were given a dividend of $0.32 per share. This represents a $1.28 annualized dividend and a dividend yield of 0.6%. The ex-dividend date of this dividend was Friday, December 26th. Danaher’s dividend payout ratio is presently 25.40%.

About Danaher

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.